Anticoagulation in Brain Hemangiomas

Risk Assessment and Indications

The American Society of Clinical Oncology recommends obtaining brain MRI with susceptibility-weighted imaging to detect acute or recent hemorrhage within the hemangioma, presence of developmental venous anomalies, and hemosiderin deposition indicating prior hemorrhage 1
Patients with brain hemangiomas require careful risk assessment of bleeding risk, particularly evaluating for recent hemorrhage on imaging, presence of developmental venous anomalies, and platelet count, before initiating anticoagulation 1
Full-dose anticoagulation requires platelets >50 × 10^9/L with no active bleeding, as recommended by the American College of Cardiology 2
Strong indications for anticoagulation include confirmed venous thromboembolism and high-risk atrial fibrillation with stroke risk, as stated by the European Society of Cardiology 3, 5

The American College of Chest Physicians recommends low molecular weight heparin as the preferred agent for anticoagulation in patients with brain hemangiomas, due to its effectiveness in preventing VTE recurrence without increasing major bleeding 3, 4
The dosing of low molecular weight heparin should be adjusted based on platelet count, with full therapeutic dose if platelets >50 × 10^9/L, half-dose with close monitoring if platelets 20-50 × 10^9/L, and avoidance if platelets <20 × 10^9/L, as recommended by the International Society on Thrombosis and Haemostasis 2
The duration of anticoagulation should be at least 6 months for VTE treatment, and continued longer if ongoing cancer treatment or active malignancy, as stated by the National Comprehensive Cancer Network 3, 4

Regular neurological assessment is necessary to evaluate for new headaches, seizures, or focal deficits indicating hemorrhage, with a lower threshold for repeat imaging if symptoms develop, as recommended by the American Academy of Neurology 1, 2
Laboratory monitoring should include regular platelet counts, especially if receiving concurrent therapies, and adjustment of anticoagulation based on platelet trends, as stated by the International Society on Thrombosis and Haemostasis 2, 3, 4
Imaging surveillance should include repeat MRI if new neurological symptoms develop, and consideration of baseline repeat imaging 1-2 weeks after starting anticoagulation to ensure stability, as recommended by the American College of Radiology 1, 6